Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Citius Pharmaceuticals is a late-stage specialty pharmaceutical company developing three primary product candidates: Lymphir (denileukin diftitox) for cutaneous T-cell lymphoma and peripheral T-cell lymphoma, LYMPHIR I/LYMPHIR II (interleukin-2 fusion protein) for autoimmune diseases, and Mino-Lok (antibiotic lock solution) for catheter-related bloodstream infections. The company is pre-revenue with negative operating cash flow, focused on advancing clinical trials and regulatory submissions. Stock performance is driven by clinical trial results, FDA regulatory milestones, and capital raising activities.
Clinical-stage biotech model: company invests in R&D to advance drug candidates through FDA approval, then monetizes through direct commercialization (specialty sales force targeting oncologists/hospitals) or licensing/partnership deals with larger pharma companies. Pricing power depends on demonstrating clinical differentiation versus existing therapies and securing favorable reimbursement from payers. Lymphir targets orphan indications with limited competition, potentially supporting premium pricing ($100K+ annual treatment costs). Mino-Lok addresses hospital-acquired infections with cost-offset value proposition (preventing expensive bloodstream infections). No current revenue; value creation tied to binary regulatory outcomes and commercial execution post-approval.
Lymphir FDA approval timeline and regulatory feedback - BLA submission status and agency interactions
Clinical trial data readouts for CTCL/PTCL efficacy and safety endpoints (response rates, progression-free survival)
Mino-Lok regulatory pathway clarity and potential partnership announcements
Capital raises and cash runway visibility - dilution concerns given negative cash flow and $0.99 current ratio
Competitive developments in CTCL/PTCL treatment landscape (biosimilars, novel therapies)
Reimbursement and payer coverage decisions for approved products
Binary FDA approval risk - single product failure can eliminate majority of company value given concentrated pipeline
Reimbursement pressure from payers and potential drug pricing legislation affecting specialty pharmaceutical economics
Clinical trial execution risk including enrollment delays, safety signals, or efficacy misses versus endpoints
Orphan drug market size limitations - CTCL/PTCL combined US prevalence under 10,000 patients annually
Established CTCL therapies including Adcetris (Seattle Genetics) and mogamulizumab (Kyowa Kirin) with proven efficacy
Biosimilar competition risk if Lymphir achieves approval - denileukin diftitox is reformulation of previously approved Ontak
Large pharma pipeline programs in T-cell lymphomas with superior resources for clinical development and commercialization
Hospital infection prevention alternatives to Mino-Lok including antimicrobial-coated catheters and systemic antibiotics
Liquidity constraint with 0.99 current ratio and negative operating cash flow requiring near-term capital raise
Dilution risk from equity financing given -331.4% FCF yield and limited non-dilutive funding options
Going concern risk if unable to secure financing before cash depletion - estimated 4-6 quarter runway based on current burn
Minimal debt capacity given pre-revenue status and negative equity returns (-54.3% ROE)
low - Pre-revenue biotech with value driven by binary regulatory outcomes rather than economic cycles. Clinical trial timelines and FDA decisions are largely independent of GDP growth. However, capital markets access for financing is cyclically sensitive, affecting ability to fund operations. Oncology drug demand is non-discretionary and recession-resistant post-launch.
Rising interest rates negatively impact valuation through higher discount rates applied to distant future cash flows (DCF models). Pre-revenue biotechs are particularly sensitive as all value is in out-years. Higher rates also increase cost of capital for dilutive equity raises and reduce investor appetite for speculative growth stocks. Current negative cash flow makes company dependent on favorable financing conditions. 10-year Treasury yields above 4.5% historically compress biotech multiples significantly.
Minimal direct credit exposure as company has negligible debt (0.01 D/E ratio). However, tight credit conditions reduce availability of venture debt or convertible financing as bridge capital between equity raises. Broader credit stress can impair partnership economics if pharma acquirers face financing constraints for M&A activity.
growth - High-risk, high-reward biotech investors seeking asymmetric returns from binary regulatory catalysts. Attracts speculative retail investors and specialized healthcare hedge funds willing to underwrite clinical/regulatory risk. Not suitable for income or value investors given no revenue, negative cash flow, and -71% one-year return. Momentum traders active around clinical data releases and FDA decision dates. Requires 3-5 year investment horizon to capture potential product launch value.
high - Biotech stocks exhibit extreme volatility around binary events (clinical data, FDA decisions). Stock down -71% over one year and -48% over six months, reflecting elevated risk and sector headwinds. Expect 20-50% single-day moves on material news. Implied volatility typically 80-120% for pre-revenue biotechs. Low float and institutional ownership amplify price swings. Beta likely 1.5-2.0x versus broader market.
